Press Releases
Calidi is at the forefront of the genetic medicine revolution in cancer and other indications
Read the Latest
Calidi Biotherapeutics Reports Second Quarter 2024 Operating and Financial Results
Launched Nova Cell subsidiary with $2 million investment from Dr. Ronald Rigor to advance Calidi’s…
Calidi Biotherapeutics Announces Launch of Nova Cell Subsidiary and $3 Million Aggregate Investment from Dr. Ronald Rigor
SAN DIEGO, July 29, 2024 (GLOBE NEWSWIRE) — Calidi Biotherapeutics, Inc. (NYSE American: CLDI or…
Calidi Biotherapeutics Announces Issuance of New U.S. Patent Covering Novel SuperNova Technology Platform
SAN DIEGO, July 18, 2024 (GLOBE NEWSWIRE) — Calidi Biotherapeutics, Inc. (NYSE American: CLDI or…
Calidi Biotherapeutics Announces Appointment of Dr. Mark Gilbert to Medical Advisory Board
Former NIH/National Cancer Institute neuro-oncology leader adds in-depth government healthcare agency expertise to Calidi SAN…
Calidi to Effect Reverse Stock Split
Calidi common stock expected to begin trading on a 1-for-10 split adjusted basis on July…
Calidi Biotherapeutics Announces Appointment of Cancer Immunotherapy Pioneer Dr. George Peoples to Board of Directors
SAN DIEGO, CALIF. — June 27, 2024 – Calidi Biotherapeutics, Inc. (NYSE American: CLDI or…